- Colorado Expands Antitrust Protection
- July 18, 2023Copyright: Rights Even Heroes Can't Protect
- UCB, Inc. v. Annora Pharma Priv. Ltd.
- Taiho Pharm. Co., Ltd. v. Eugia Pharma Specialties Ltd.
- August 2023Minnesota Passes Survivorship Bill, Expanding Justice for Victims of Medical Malpractice and Wrongful Death
- August 2023Minnesota Bans Non-Competes Formed on or After July 1, 2023: Assessing Remaining Strategies to Protect Confidential Information and Trade Secrets
- August 7, 2023Pointers For Tackling Antitrust Class Action Set-Aside Orders
- Second QuarterGenerically Speaking: A Hatch-Waxman Litigation Bulletin
- Mallory Gives Plaintiffs a Better Shot at Justice
- United Therapeutics Corp. v. Liquidia Technologies, Inc.
- Second QuarterANDA Approvals
- Second QuarterANDA Litigation Settlements
- Second QuarterGeneric Launches
- Second QuarterNew ANDA Cases
- Orexo AB v. Sun Pharm. Indus. Ltd.
- July 7, 2023PTAB Overruled: A New Analysis For Real Party In Interest
- July 7, 2023In re Entresto Patent Litigation
- July 6, 2023Artistry No Excuse for Trademark Infringement Where Use is Source Identifying
- July 6, 2023Novartis Pharms. Corp. v. Mylan Pharms. Inc.
- July 2023The Sedona Conference Commentary on the Governance and Management of Trade Secrets
- Sanofi-Aventis U.S. LLC v. Sandoz, Inc.
- June 2023On the Emotional Costs of Litigation
- June 2023Chaos v. Predictability: The Enforceability of Choice of Law Provisions
- June 2023Attorney Spotlight: Partner Christina M. Lincoln
- June 2023I Love Insurance and My Dog: Pet Insurance 101
- June 2023Understanding Fiduciary Duties and Obligations in Investment and Divestment
- June 2023Top Five Writing Tips for Everyday Writing
- June 2023The Blame Game: Can Cyber Crimes Fall Under the War Exclusion?
- June 2023Lessons from the Trial Trenches: How to Avoid Large Adverse Verdicts
- June 2023Marina Pacific: A Rare Glimpse into a Pandemic-Related Property Coverage Trial
- June 9, 2023Astellas Pharma Inc. v. Sandoz Inc.
- May 2023Raoul Shah: Keeping Humanity and Compassion Close
- Janssen Pharms., Inc. v. Mylan Labs. Ltd.
- 2023 Bulletin - First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin 2023 Q1
- In re Sugammadex
- Vanda Pharms. Inc. v. Teva Pharms. USA, Inc.
- Azurity Pharms., Inc. v. Alkem Labs. Ltd.
- Bristol-Myers Squibb Co. v. Xspray Pharma AB
- Drafting Subsequent Agreements to Avoid Arbitrability Litigation
- Amgen Inc. v. Sandoz Inc.
- March 2023Achieving the Largest Jury Verdict in Minnesota History
- UCB, Inc. v. Actavis Labs. UT, Inc.
- First QuarterANDA Approvals
- First QuarterANDA Litigation Settlements
- Purdue Pharma L.P. v. Accord Healthcare Inc.
- First QuarterGeneric Launches
- First QuarterNew ANDA Cases
- Bristol-Myers Squibb Co. v. Nanocopoeia, LLC
- March 2023Unintended Consequences of Banning Noncompete Agreements
- What I’ll Be Watching for in the Amgen Oral Arguments
